Listening Sessions on Diversity, Equity, and Inclusion – Hematology.org

Listening Sessions on Diversity, Equity, and Inclusion

ASH Meeting on Hematologic Malignancies Social Sharing Toolkit

Spread the word about the ASH Meeting on Hematologic Malignancies: A Virtual Experience with this social media toolkit.

Volume 136 Issue 9 | Blood | American Society of Hematology

Read the current issue of Blood.

VTE in ICU Patients With COVID-19

Written by Vahid Afshar-Kharghan MD

Novel STAMP Inhibitor Asciminib Meets Primary End Point in Phase 3 Study of Chronic Myeloid Leukemia

The primary end point of statistically superiority in major molecular response rate at 24 weeks was met with asciminib versus bosutinib as treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the phase 3 ASCEMBL study.

Severe COVID-19 Infection in Patients With Hematological Disorders Receiving Chemo- or Immunotherapy

Read it now on PracticeUpdate.com

Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia – The ASCO Post

SWG on Aging and Hematology

The SWG

Hematological Characteristics and Risk Factors in the Classification and Prognosis Evaluation of COVID-19

Read it now on PracticeUpdate.com

International Society on Thrombosis and Haemostasis Virtual Congress 2020

Christoph Königs (Frankfurt, Germany) presented the final results of the phase 3 PUPs A-LONG study (NCT02234323). 103 previously untreated patients (<6 years) with haemophilia A were treated with an extended half-life recombinant factor VIII Fc fusion protein. The primary endpoint was the incidence of inhibitor development. A secondary endpoint was annualised bleeding rate. 87 patients completed...